View graph of relations
  1. 2019
  2. Published
  3. 2018
  4. Published
  5. Published
  6. Published
  7. Published
  8. Published
  9. Published
  10. Published
    Smolders, J., Hupperts, R., & Damoiseaux, J. (2018). Chapter 8 - The Way Forward With Vitamin D in Multiple Sclerosis. In A. Minagar (Ed.), Neuroinflammation (Second Edition) (pp. 175-191). Academic Press. https://doi.org/10.1016/B978-0-12-811709-5.00009-0
  11. 2017
  12. Published
    Havrdova, E., Arnold, D. L., Cohen, J. A., Hartung, H-P., Fox, E. J., Giovannoni, G., ... Coles, A. J. (2017). Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. Neurology, 89(11), 1107-1116. https://doi.org/10.1212/WNL.0000000000004313
  13. Published
    Coles, A. J., Cohen, J. A., Fox, E. J., Giovannoni, G., Hartung, H-P., Havrdova, E., ... Arnold, D. L. (2017). Alemtuzumab CARE-MS II 5-year follow-up Efficacy and safety findings. Neurology, 89(11), 1117-1126. https://doi.org/10.1212/wnl.0000000000004354
  14. Published
    Lorscheider, J., Jokubaitis, V. G., Spelman, T., Izquierdo, G., Lugaresi, A., Havrdova, E., ... Kalincik, T. (2017). Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. Neurology, 89(10), 1050-1059. https://doi.org/10.1212/WNL.0000000000004330
  15. Published
    Kalincik, T., Manouchehrinia, A., Sobisek, L., Jokubaitis, V., Spelman, T., Horakova, D., ... MSBase Study Group (2017). Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain, 140(9), 2426-2443. https://doi.org/10.1093/brain/awx185
  16. Published
  17. Published
  18. Published
    de Jong, H. J. I., Kingwell, E., Shirani, A., Tervaert, J. W. C., Hupperts, R., Zhao, Y., ... British Columbia Multiple Sclerosi (2017). Evaluating the safety of beta-interferons in MS A series of nested case-control studies. Neurology, 88(24), 2310-2320. https://doi.org/10.1212/WNL.0000000000004037
  19. Published
  20. Published
    Iaffaldano, P., Simone, M., Lucisano, G., Ghezzi, A., Coniglio, G., Morra, V. B., ... Trojano, M. (2017). Prognostic Indicators in Pediatric Clinically Isolated Syndrome. Annals of Neurology, 81(5), 729-739. https://doi.org/10.1002/ana.24938
  21. Published
  22. Published
    Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., ... Wolinsky, J. S. (2017). Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New England Journal of Medicine, 376(3), 209-220. https://doi.org/10.1056/NEJMoa1606468
  23. Published
  24. Published
  25. 2016
  26. Published
    Claes, N., Fraussen, J., Vanheusden, M., Hellings, N., Stinissen, P., Van Wijmeersch, B., ... Somers, V. (2016). Age-Associated B Cells with Proinflammatory Characteristics Are Expanded in a Proportion of Multiple Sclerosis Patients. Journal of Immunology, 197(12), 4576-4583. https://doi.org/10.4049/jimmunol.1502448
  27. Published
    Fraussen, J., Claes, N., Van Wijmeersch, B., van Horssen, J., Stinissen, P., Hupperts, R., & Somers, V. (2016). B cells of multiple sclerosis patients induce autoreactive proinflammatory T cell responses. Clinical Immunology, 173, 124-132. https://doi.org/10.1016/j.clim.2016.10.001
  28. Published
  29. Published
  30. Published
  31. Published
  32. Published
    Kister, I., Spelman, T., Alroughani, R., Lechner-Scott, J., Duquette, P., Grand'Maison, F., ... Butzkueven, H. (2016). Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. Journal of Neurology Neurosurgery and Psychiatry, 87(10), 1133-1137. https://doi.org/10.1136/jnnp-2016-313760
  33. Published
  34. Published
    Lorscheider, J., Buzzard, K., Jokubaitis, V., Spelman, T., Havrdova, E., Horakova, D., ... Kalincik, T. (2016). Defining secondary progressive multiple sclerosis. Brain, 139, 2395-2405. https://doi.org/10.1093/brain/aww173
  35. Published
  36. Published
  37. Published
  38. Published
    Jokubaitis, V. G., Spelman, T., Kalincik, T., Lorscheider, J., Havrdova, E., Horakova, D., ... Trojano, M. (2016). Predictors of Long-Term Disability Accrual in Relapse-Onset Multiple Sclerosis. Annals of Neurology, 80(1), 89-100. https://doi.org/10.1002/ana.24682
  39. Published
  40. Published
    Spelman, T., Kalincik, T., Jokubaitis, V., Zhang, A., Pellegrini, F., Wiendl, H., ... Butzkueven, H. (2016). Comparative efficacy of first-line natalizumab vs IFN-beta or glatiramer acetate in relapsing MS. Neurology: Clinical Practice, 6(2), 102-115. https://doi.org/10.1212/CPJ.0000000000000227
  41. Published
  42. Published
  43. Published
  44. Published
  45. 2015
  46. Published
    Kalincik, T., Cutter, G., Spelman, T., Jokubaitis, V., Havrdova, E., Horakova, D., ... Butzkueven, H. (2015). Defining reliable disability outcomes in multiple sclerosis. Brain, 138. https://doi.org/10.1093/brain/awv258
  47. Published
  48. Published
    Kalincik, T., Jokubaitis, V., Izquierdo, G., Duquette, P., Girard, M., Grammond, P., ... Butzkueven, H. (2015). Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 21(9), 1159-1171. https://doi.org/10.1177/1352458514559865
  49. Published
    Ribbons, K. A., McElduff, P., Boz, C., Trojano, M., Izquierdo, G., Duquette, P., ... Lechner-Scott, J. (2015). Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. PLOS ONE, 10(6), [e0122686]. https://doi.org/10.1371/journal.pone.0122686
  50. Published
    Bergamaschi, R., Montomoli, C., Mallucci, G., Lugaresi, A., Izquierdo, G., Grand'Maison, F., ... Trojano, M. (2015). BREMSO: a simple score to predict early the natural course of multiple sclerosis. European Journal of Neurology, 22(6), 981-989. https://doi.org/10.1111/ene.12696
  51. Published
    Jokubaitis, V. G., Spelman, T., Kalincik, T., Izquierdo, G., Grand'Maison, F., Duquette, P., ... Trojano, M. (2015). Predictors of disability worsening in clinically isolated syndrome. Annals of Clinical and Translational Neurology, 2(5), 479-491. https://doi.org/10.1002/acn3.187
  52. Published
    Spelman, T., Kalincik, T., Zhang, A., Pellegrini, F., Wiendl, H., Kappos, L., ... Butzkueven, H. (2015). Comparative efficacy of switching to natalizumab in active multiple sclerosis. Annals of Clinical and Translational Neurology, 2(4), 373-387. https://doi.org/10.1002/acn3.180
  53. Published
    He, A., Spelman, T., Jokubaitis, V., Havrdova, E., Horakova, D., Trojano, M., ... Kalincik, T. (2015). Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. JAMA Neurology, 72(4), 405-413. https://doi.org/10.1001/jamaneurol.2014.4147
  54. Published
  55. Published
    Kalincik, T., Horakova, D., Spelman, T., Jokubaitis, V., Trojano, M., Lugaresi, A., ... Butzkueven, H. (2015). Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis. Annals of Neurology, 77(3), 425-435. https://doi.org/10.1002/ana.24339
Previous 1 2 3 Next